874 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bought by World Investment Advisors

World Investment Advisors purchased a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 874 shares of the pharmaceutical company's stock, valued at approximately $424,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Quent Capital LLC grew its holdings in shares of Vertex Pharmaceuticals by 4.5% during the first quarter. Quent Capital LLC now owns 513 shares of the pharmaceutical company's stock worth $249,000 after buying an additional 22 shares in the last quarter. Truvestments Capital LLC boosted its position in shares of Vertex Pharmaceuticals by 30.3% in the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock worth $40,000 after acquiring an additional 23 shares during the last quarter. Moors & Cabot Inc. boosted its position in shares of Vertex Pharmaceuticals by 0.7% in the fourth quarter. Moors & Cabot Inc. now owns 3,603 shares of the pharmaceutical company's stock worth $1,451,000 after acquiring an additional 25 shares during the last quarter. Sculati Wealth Management LLC boosted its position in shares of Vertex Pharmaceuticals by 1.0% in the fourth quarter. Sculati Wealth Management LLC now owns 2,556 shares of the pharmaceutical company's stock worth $1,029,000 after acquiring an additional 25 shares during the last quarter. Finally, Avidian Wealth Enterprises LLC boosted its position in shares of Vertex Pharmaceuticals by 2.1% in the first quarter. Avidian Wealth Enterprises LLC now owns 1,225 shares of the pharmaceutical company's stock worth $594,000 after acquiring an additional 25 shares during the last quarter. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Stock Down 2.2%

Shares of NASDAQ VRTX traded down $10.68 during trading on Friday, reaching $468.85. 892,738 shares of the stock were exchanged, compared to its average volume of 1,424,305. The business's 50-day moving average price is $447.71 and its 200 day moving average price is $460.40. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88. The company has a quick ratio of 2.29, a current ratio of 2.65 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $120.40 billion, a price-to-earnings ratio of -119.60 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). The company had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The firm's quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the firm posted $4.76 EPS. As a group, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on VRTX. Needham & Company LLC reissued a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Leerink Partners reissued a "market perform" rating and issued a $503.00 target price (down from $550.00) on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. JPMorgan Chase & Co. raised their target price on shares of Vertex Pharmaceuticals from $512.00 to $515.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 6th. The Goldman Sachs Group reissued a "buy" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Finally, Royal Bank Of Canada set a $420.00 target price on shares of Vertex Pharmaceuticals and gave the stock a "sector perform" rating in a research report on Tuesday, June 17th. Fourteen investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $511.62.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.